Ampio enrolls patients in COVID-19 clinical trial

By The Science Advisory Board staff writers

July 23, 2020 -- Ampio Pharmaceuticals has begun patient enrollment for its previously announced COVID-19 phase I clinical trial to evaluate its Ampion drug candidate.

Ampion is based on an immunomodulatory molecule derived from the N-terminus of the human serum albumin. The trial will evaluate its intravenous application as a treatment for patients with COVID-19 who are on supplemental oxygen.


Copyright © 2020 scienceboard.net
 


MemberID or email address:  

Password:  
Forgot your password?